Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

256.84 2.10 +0.82%
Market cap
$28.0B
P/E
25.0×
Fwd P/E
24.4×
Dividend yield
1.33%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100

Quest Diagnostics Incorporated 10-Q filed Jul 24, 2024

Fiscal Q2 2024 · Period ended Jun 30, 2024 · Filed · accepted 4:44 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov